Please assess the completion status of the following clinical trial:

Trial Title: PETHEMA-BLIN-01/PET069014 (BLIN-01)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women between 18 to 55 years of age, both inclusive.~* Patients with Philadelphia chromosome-negative or BCR-ABL-negative, CD19-positive ALL, with high-risk characteristics. The definition of high-risk ALL implies the presence of one or more of the following factors: Aged 30-55 years; Leukocytes \> 30×109/l in B-precursor ALL; Any of the following cytogenetic or molecular abnormalities: 11q23 abnormalities, or proven MLL rearrangement; Complex karyotype (more than 5 chromosome abnormalities); Pro-B ALL, regardless of the number of leukocytes.~* Previous treatment according to routine clinical practice in Spanish centres, in accordance with the PETHEMA protocol for patients with high-risk ALL (ALL-AR-11), in complete remission (MRD \< 0.1%) (\< 1×10-3) centralised assessment through flow cytometry) after induction therapy.~* ECOG \< 2.~* Ability to understand the study and willingness to sign the written informed consent form~Exclusion Criteria:~* Philadelphia chromosome-positive (Ph+) ALL.~* Burkitt's leukaemia (mature B phenotype) according to the WHO classification.~* T-cell ALL.~* B-precursor ALL with high-risk characteristics and MRD ≥ 0.1% (≥ 1×10-3) after receiving induction chemotherapy.~* Previous history or presence of a clinically significant disease of the central nervous system (CNS): epilepsy, seizures, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis.~* Presence or history of an autoimmune disease potentially affecting the CNS.~* Radiotherapy in the 2 weeks prior to starting treatment with blinatumomab.~* Immunotherapy (e.g., rituximab) within 4 weeks prior to starting treatment with blinatumomab.~* Any investigational product for leukaemia in the 4 weeks prior to starting treatment with blinatumomab.~* Treatment with any investigational medicinal product after signing the informed consent form.~* Candidate patient for allogeneic haematopoietic stem cell transplantation (HSCT) at the time of enrolment.~* Known hypersensitivity to human immunoglobulins or to any component of the investigational product.~* Abnormal laboratory values: AST (SGOT) and/or ALT (SGPT) and/or alkaline phosphatase ≥ 5 ULN;total bilirubin ≥ 1.5 ULN (unless related to Gilbert's syndrome or Meulengracht's disease); Creatinine ≥ 1.5 ULN; Estimated creatinine clearance \< 50 ml/min; Haemoglobin ≥ 9 g/dl (transfusion permitted).~* History of malignant disease other than ALL in the 5 years prior to starting treatment with blinatumomab, with the exception of basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.~* Active uncontrolled infection, or any other concurrent disease or medical condition considered to interfere with the conduct of the study as per the investigator's discretion.~* HIV infection or chronic hepatitis B virus (HBsAg positive) or hepatitis C virus infection (anti-HCV positive).~* Pregnant or breast-feeding women.~* Women of childbearing potential who are not willing use an effective method of contraception during their participation in the study and for at least 3 months thereafter. Men who are not willing to take measures to prevent their partner from becoming pregnant during their participation in the study and for at least 3 months thereafter.~* Prior treatment with blinatumomab.~* Patients who do not want or are unable to meet the protocol requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- blinatumomab (Type: EXPERIMENTAL): blinatumomab administered during the early consolidation phase in patients ≤ 55 years with high-risk Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukaemia (ALL) with MRD \< 0.1% (\< 1×10-3) after induction therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).